ONCY
Income statement / Annual
Last year (2023), Oncolytics Biotech Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Oncolytics Biotech Inc.'s net income was -$27.75 M.
See Oncolytics Biotech Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$403,000.00 |
$392,000.00 |
$452,065.00 |
$446,187.00 |
$485,574.00 |
$95,375.00 |
$90,768.00 |
$162,233.00 |
$180,411.00 |
$0.00 |
| Gross Profit |
-$403,000.00 |
-$392,000.00 |
-$452,065.00 |
-$446,187.00 |
-$485,574.00 |
-$95,375.00 |
-$90,768.00 |
-$162,233.00 |
-$180,411.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$17.71 M
|
$15.43 M
|
$12.92 M
|
$12.94 M
|
$11.13 M
|
$9.42 M
|
$9.39 M
|
$9.77 M
|
$8.60 M
|
$13.82 M
|
| General & Administrative
Expenses |
$16.08 M
|
$11.49 M
|
$13.32 M
|
$12.51 M
|
$0.00
|
$0.00
|
$0.00
|
$5.36 M
|
$5.14 M
|
$0.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
-$452,491.00
|
-$445,691.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$16.08 M
|
$11.49 M
|
$12.86 M
|
$12.07 M
|
$8.84 M
|
$7.08 M
|
$6.21 M
|
$5.36 M
|
$5.14 M
|
$5.00 M
|
| Other Expenses |
$0.00 |
$0.00 |
$13.31 M |
$12.51 M |
$9.56 M |
$7.24 M |
$6.21 M |
$162,233.00 |
$180,411.00 |
$5.00 M |
| Operating Expenses |
$33.79 M |
$26.92 M |
$26.23 M |
$25.46 M |
$20.69 M |
$16.66 M |
$15.61 M |
$15.29 M |
$13.92 M |
$18.82 M |
| Cost And Expenses |
$33.79 M |
$26.92 M |
$26.23 M |
$25.46 M |
$20.69 M |
$16.66 M |
$15.61 M |
$15.29 M |
$13.92 M |
$18.82 M |
| Interest Income |
$1.33 M |
$528,000.00 |
$98,612.00 |
$121,194.00 |
$179,277.00 |
$173,496.00 |
$130,101.00 |
$163,902.00 |
$197,859.00 |
$210,390.00 |
| Interest Expense |
$0.00 |
$528,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$81,000.00
|
$392,000.00
|
$452,065.00
|
$446,187.00
|
$485,574.00
|
$95,375.00
|
$90,768.00
|
$162,233.00
|
$180,411.00
|
$163,501.00
|
| EBITDA |
-$33.71 M
|
-$26.83 M
|
-$25.66 M
|
-$25.37 M
|
-$20.02 M
|
-$17.18 M
|
-$15.51 M
|
-$15.13 M
|
-$13.74 M
|
-$18.66 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$6.14 M
|
$2.17 M
|
-$20,055.00
|
$2.95 M
|
-$12.43 M
|
$173,496.00
|
$130,101.00
|
$163,902.00
|
$197,859.00
|
$210,390.00
|
| Income Before Tax |
-$27.66 M |
-$24.75 M |
-$26.25 M |
-$22.51 M |
-$33.12 M |
-$16.49 M |
-$15.48 M |
-$15.13 M |
-$13.72 M |
-$18.61 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$97,000.00 |
$84,000.00 |
$49,427.00 |
-$2.95 M |
$12.43 M |
$548,042.00 |
$141,498.00 |
$9,374.00 |
$3,153.00 |
$6,779.00 |
| Net Income |
-$27.75 M |
-$24.84 M |
-$26.30 M |
-$19.55 M |
-$45.55 M |
-$17.04 M |
-$15.62 M |
-$15.14 M |
-$13.72 M |
-$18.62 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-0.41 |
-0.43 |
-0.49 |
-0.48 |
-2.06 |
-1.06 |
-1.12 |
-1.2 |
-1.16 |
-2.01 |
| EPS Diluted |
-0.41 |
-0.43 |
-0.49 |
-0.48 |
-2.06 |
-1.06 |
-1.12 |
-1.2 |
-1.16 |
-2.01 |
| Weighted Average Shares
Out |
$67.62 M
|
$58.03 M
|
$53.51 M
|
$40.34 M
|
$22.14 M
|
$16.02 M
|
$13.94 M
|
$12.62 M
|
$11.85 M
|
$9.25 M
|
| Weighted Average Shares
Out Diluted |
$67.62 M
|
$58.03 M
|
$53.51 M
|
$40.34 M
|
$22.14 M
|
$16.02 M
|
$13.94 M
|
$12.62 M
|
$11.85 M
|
$9.25 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
